Table 1.

ADR Survey: study participant characteristics

	Maputo (N = 642)			Tete (N = 471)
	N	% or median	95% CI or IQR	N	% or median	IQR
Gender
Female	435	67.8	63.9–71.3	319	67.7
Male	207	32.2	28.6–30.0	152	32.4
Age, years, median [IQR]		44	[37–52]		38	[31–46]
18–35	136	21.2	18.1–24.5	198	42.0
36–49	297	46.2	42.3–50.2	190	40.3
≥50	209	32.6	28.9–36.3	83	17.6
CD4 count, cells/mm3, median [IQR]		492	[476–510]		529	[365–703]
<200	44	6.9	5.0–9.0	38	8.0
200–350	133	20.7	17.6–24.0	72	15.3
≥350	465	72.4	68.8–75.8	361	76.7
WHO stage
Stage 1	631	98.2	96.9–99.1	452	96.0
Stage 2	11	1.8	0.8–3.0	7	1.4
Stage 3	–	–	–	12	2.6
Time on ART, years, median [IQR]		4.5	[2.4–6.9]		3.2	[1.6–5.6]
6–24 months	134	20.8	17.8–24.2	147	31.1
≥25 months	508	79.2	75.7–82.2	324	68.9
ART regimen at ART initiation
TDF-containing regimens	293	45.6		297	63.0
ZDV-containing regimens	307	47.8		173	36.8
Other/Not available	41	6.6		1	0.2
Current ART regimen
TDF/(3TC or ABC)/EFV	529	82.4	79.2–85.3	400	84.9
ZDV/3TC/(EFV or NVP)	113	17.6	14.4–20.4	71	15.1

TDF, tenofovir; 3TC, lamivudine; ABC, abacavir; EFV, efavirenz; ZDV, zidovudine; NVP, nevirapine.